Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01387087 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K
A Phase 1 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT01387087 is a Phase 1 study that has completed, run by Astellas Pharma. The registered enrollment target is 72 participants.
The verdict
NCT01387087, a Phase 1 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
The objective of the study is to explore safety and tolerability of single ascending doses of ASP015K, establish the maximum tolerated dose, and determine the pharmacokinetics and pharmacodynamics in healthy volunteers.
Interventions
- DRUG Placebo
- DRUG ASP015K
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2008-07 |
| Est. Completion | 2008-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01387087
The ClinicalTrials.gov registry entry for NCT01387087 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01387087 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01387087 about?
NCT01387087 is a clinical study titled "A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K". The objective of the study is to explore safety and tolerability of single ascending doses of ASP015K, establish the maximum tolerated dose, and determine the pharmacokinetics and pharmacodynamics in healthy volunteers.
What is the current status of trial NCT01387087?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2008-07. Estimated completion is 2008-11.
What interventions are being tested in trial NCT01387087?
The interventions under investigation include: Placebo (DRUG), ASP015K (DRUG).
Who is sponsoring clinical trial NCT01387087?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.